Halozyme Raises 2025 Revenue, EPS Guidance Amid Strong Q3 Results

Halozyme Therapeutics reported strong third-quarter financial results, with net income rising to $175.2 million and adjusted earnings reaching $1.72 per share, both surpassing analyst expectations. The company's revenue increased by 22% to $354.3 million, driven primarily by soaring royalties from its ENHANZE platform, notably from therapies like DARZALEX SC, Phesgo, and VYVGART Hytrulo. Halozyme raised its 2025 revenue forecast to a range of $1.3 billion to $1.375 billion and adjusted earnings per share guidance to between $6.10 and $6.50, reflecting confidence in sustained growth. Recent regulatory approvals in Europe and Japan further support the expansion of its ENHANZE-enabled therapies globally. Despite strong financial health and robust margins, the company faces some insider selling and relies moderately on debt financing. Additionally, Halozyme announced that its finance chief, Nicole LaBrosse, will depart by March 2026 as the company begins a search for her replacement.